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Introduction {#sec1}
============

Single-cell RNA sequencing (scRNA-seq) is a powerful technique that enables gene expression measurements in thousands of individual cells. Resolving cellular heterogeneity by scRNA-seq has enabled groundbreaking discovery in the biomedical domain, such as finding key disease drivers in cancer ([@bib24]; [@bib26]; [@bib37]), neurodegeneration ([@bib14]; [@bib21]), and immune-mediated diseases ([@bib8]; [@bib31]; [@bib36]; [@bib44]). From a data analysis standpoint, a crucial step in a standard scRNA-seq pipeline is clustering ([@bib18]), where discrete cell populations sharing a common transcriptional profile are defined. These cell clusters are used in a variety of downstream analyses, such as differential expression ([@bib7]; [@bib19]; [@bib32]), compositional analysis ([@bib11]), and cellular interaction analysis ([@bib38]; [@bib43]; [@bib46]). Phenotypic identification of clusters is usually performed by means of a hybrid approach that entails prior knowledge of the biological system and gene set enrichment analysis on cluster markers. An alternative, cluster-free approach to phenotypic identification of cellular states is trajectory analysis ([@bib29]), which aims to derive differentiation processes by using a pseudo-temporal ordering of single cells. However, in addition to identity- and differentiation-specific activities, transcriptional programs encompass a variety of cellular processes such as metabolism, growth, stress, and cell signaling, which are not necessarily captured by these approaches. Nevertheless, such expression programs are of great interest in a disease setting, where several communicating cell populations might act within the same dysregulated pathway. Thus, an in-depth characterization of such pathogenic signaling cascades at single-cell resolution is of great interest from a disease understanding perspective.

Latent factor models aim to decompose the global expression profile in its underlying transcriptional programs ([@bib33]). These models project both genes and cells in a low-dimensional space, with latent dimensions approximating cells\' transcriptional programs and summarizing the contributions of several genes. Standard matrix factorization approaches, such as principal component analysis (PCA), non-negative matrix factorization (NMF), and independent component analysis (ICA), have been widely applied to scRNA-seq data ([@bib15]). Nevertheless, novel methods have been developed that account for the specificities of single-cell data, using meaningful prior distributions and enforcing sparsity ([@bib2]; [@bib3]; [@bib16]; [@bib17]; [@bib25]; [@bib34]). A key parameter choice of these methods that is left to the analyst is the number of latent dimensions to use. Despite a few heuristics having been proposed based on stability analysis or model selection ([@bib2]; [@bib15]; [@bib34]; [@bib40]), it is unclear whether these strategies could be applied effectively to datasets with different characteristics and whether such heuristics are appropriate for different downstream tasks. For example, it has been shown that different biological processes are captured at different dimensionalities of the latent space ([@bib40]), suggesting that approaches considering a varying number of latent dimensions could be more robust in fully recapitulating the underlying biology of the dataset under consideration.

To explore the potential of this family of methods to uncover previously unidentified pathway activities, we perform a systematic comparison of four recent latent factor models that specifically account for the sparsity of scRNA-seq data: scCoGAPS ([@bib34]), LDA ([@bib2]; [@bib9]), scHPF ([@bib16]), and scVI ([@bib17]; [@bib35]). The first three methods are built on probabilistic approaches to matrix factorization and have been successfully used to extract gene signatures from scRNA-seq data ([@bib5]; [@bib35]; [@bib42]; [@bib45]), whereas the last one is based on a deep variational autoencoder with a linear decoder, making the inferred gene weights interpretable ([@bib35]). We test these on two scRNA-seq datasets from patients with autoimmune diseases. The first dataset consists of single cells isolated from synovial biopsies of patients with rheumatoid arthritis (RA) and sorted into four main cell subsets: monocytes, B cells, T cells, and fibroblasts (referred to as the RA dataset) ([@bib44]). The second dataset consists of single cells isolated from the kidney of patients with systemic lupus erythematosus (SLE) with lupus nephritis (LN) and enriched for the leukocyte component (referred to as the SLE dataset) ([@bib36]). We evaluate the stability over iterations of the four methods across the dimensionality of the latent space by using three different metrics and highlight the predictive power of these methods to discriminate cells isolated from patients or controls. Then, we assess the methods\' ability to recover gene signatures by evaluating the coverage across 13 different gene set collections. Reasoning that latent factors can be used as surrogates of pathway activities, we devise a simple method to assign gene signatures to cell clusters, thus enabling the identification of cell subsets from a functional perspective. We then extend this analytical framework to integrate ligand -- receptor interactions across cell subsets. Finally, we explore the reported gene signatures and discover two previously unidentified pathways in the RA dataset: the OSMR signaling pathway in a subpopulation of fibroblasts and the MERTK signaling pathway in a monocyte subset. We show that these signatures are potentially disease associated, thus highlighting the power of latent factor modeling to inform the discovery of novel pathogenic pathways.

Results {#sec2}
=======

Evaluation of Latent Factor Models Show Differences in Performance across Tasks and Latent Dimensions {#sec2.1}
-----------------------------------------------------------------------------------------------------

It has been shown that factorization solutions are not strictly convex, thus resulting in different outputs for different iterations of the algorithms ([@bib15]; [@bib22]). A common heuristics to select an appropriate latent dimension is to calculate the algorithm\'s stability across iterations and select the number of dimensions with results that are more consistent across iterations ([@bib15]; [@bib41]). For each method, we performed 10 iterations across 13 dimensionalities of the latent space (from k = 16 to k = 40, with step 2) and computed three stability metrics: Amari distance, silhouette score on the k-medoids-defined clusters, and the singular value canonical correlation analysis (SVCCA) score ([@bib27]) (see [Methods](#sec4){ref-type="sec"} for details). We performed this evaluation for both the RA and the SLE datasets ([Figures 1](#fig1){ref-type="fig"}A and 1B). scCoGAPS and LDA emerge as having better stability properties, across latent dimensions as well as across the three chosen metrics. In contrast, scVI shows poor stability, showing better performance than scHPF only for the SVCCA score. Overall, all methods report a lower performance as the number of latent dimension increases, consistent with the increased model complexity. End-of-training values for the objective functions of the four methods, at different values of k, were also investigated ([Figures S1](#mmc1){ref-type="supplementary-material"}A and S1B).Figure 1Evaluation of Latent Factor Models Show Differences in Performance across Tasks and Latent Dimensions(A and B) Stability metrics in (A) the RA dataset and (B) the SLE dataset. Y axis reports the mean value of the metric across 10 iterations. X axis reports k, the number of latent dimensions.(C) Cross-validation AUPR curve in a disease-control classification task using latent variables as predictors, in the RA dataset and the SLE dataset. Y axis reports cross-validation AUPR value across 10 iterations. X axis reports k, the number of latent dimensions.(D) Mean gene set collection coverage across latent dimensions, in the RA dataset and the SLE dataset. Y axis reports mean collection coverage value, averaged across 13 gene set collections. X axis reports k, the number of latent dimensions.

To assess whether these latent factors retained information on the disease state of the samples, we used them as predictors of an elastic net regression model with the task of classifying disease and control cells ([Figures 1](#fig1){ref-type="fig"}C, [S1](#mmc1){ref-type="supplementary-material"}C, and S1D). Interestingly, we found the performance to vary considerably between datasets, but not methods. In the RA dataset, almost all methods fail to reach an AUPR \>0.5 regardless of the dimensionality of the latent space. In contrast, for the SLE dataset, all methods see a consistent increase in predictive power as the dimensionality increases, with scCoGAPS and LDA showing the best performance at low (16--24) and high (26--40) dimensionality of the latent space, respectively. Taken together, these results suggest that the dimensionality of the latent space is critical for extracting biological features related to the disease state of the cell.

The ability of latent factor models to recover biological signal is a key feature in their application to discover cellular phenotypes. Gene set enrichment analysis is a widely used approach for this task, as it allows mapping each latent variable to a specific pathway or biological process. To evaluate the methods\' ability to recapitulate biologically meaningful gene signatures in a systematic manner, we used an enrichment approach based on heterogeneous network ([@bib13]; [@bib40]). Briefly, at each dimensionality of the latent space, we compute the gene set coverage score (number of unique gene sets significantly associated with each latent variable divided by the total number of gene set in the collection) for the gene set collection of interest (see [Methods](#sec4){ref-type="sec"} for details). We considered thirteen gene set collections, covering most of the known pathways and biological processes, as well as several other gene signatures ([Figure 1](#fig1){ref-type="fig"}D). As expected, for all methods we could observe an increase in the gene set coverage as the dimensionality of the latent space increases. By comparing the gene set coverage on the latent variables with the standard enrichment on clusters\' marker genes ([Figure S1](#mmc1){ref-type="supplementary-material"}E), we showed that the number of significant gene sets is an order of magnitude higher for the factorization methods, pointing to a higher sensitivity in the discovery of pathway activities. Interestingly, scHPF clearly outperformed the other methods in the majority of the gene set collections in both datasets ([Figures S1](#mmc1){ref-type="supplementary-material"}F and S1G). This suggests that scHPF can decompose the expression matrix in a latent space that retains the highest degree of biological signal, which prompted us to use this method for all downstream analyses.

Systematic Assignment of Latent Variables to Cell Clusters Allows Identification of Cell Types Based on Their Phenotype or Function {#sec2.2}
-----------------------------------------------------------------------------------------------------------------------------------

An open challenge in single-cell transcriptomics is the phenotypic identification of cell populations after clustering. Usually, this is performed by means of a combination of prior knowledge of cell-specific markers and gene set enrichment analysis performed on the marker genes list for each cell subset ([@bib18]). However, as latent variables provide a surrogate of pathway activities across cells, we devised a simple framework to assign each pathway to cell clusters ([Figure 2](#fig2){ref-type="fig"}A). This approach directly allows the identification of cell subsets in a function- or phenotype-driven way. Briefly, we start by employing a standard clustering procedure to identify cell subsets (see [Methods](#sec4){ref-type="sec"}). For each gene set, we collapse redundant assignments to multiple latent variables in unique pathway activities, by means of an iterative clustering approach. Then, we regress pathway activity weights (i.e., the numerical results of the factorization) using the cell cluster labels as predictors. The coefficient of each cluster represents an indicator of how important that cell subset is to explain the pathway activity, therefore linking the activity of the pathway to the cell cluster, which can then be functionally interpreted. The heatmap in [Figure 2](#fig2){ref-type="fig"}B shows the coefficients for the most significant KEGG gene sets mapped to the latent variables obtained from the RA dataset, across the different cell clusters. Interestingly, broadly defined cell populations cluster together, showing that consistent activities across different biological processes recapitulate cell lineages. Importantly, this approach allows discovery of pathway activities that are unique to specific cell types or that are shared across different cell subsets in an unsupervised way. For instance, "B cell signaling" and "NK cell cytotoxicity" pathways ([Figures 2](#fig2){ref-type="fig"}C and 2D) show a distinct activity in the expected cell populations (see [Figure S1](#mmc1){ref-type="supplementary-material"}H and S1I for an overview of the identified clusters). This strategy can also be used to annotate known, yet unidentified, cell types, such as plasmacytoid dendritic cells ([Figure 2](#fig2){ref-type="fig"}E). Finally, in the SLE dataset, we could identify a type I interferon signature specifically active in a distinct subset of B cells and T cells, as previously reported ([@bib36]) ([Figure 2](#fig2){ref-type="fig"}F). Overall, this framework to define pathway activities is a powerful approach to assign cell identity and cell states to clusters based on their function or phenotype. Complete results for the RA and SLE datasets are reported in [Figures S2](#mmc1){ref-type="supplementary-material"} and [S3](#mmc1){ref-type="supplementary-material"} and [Tables S1](#mmc2){ref-type="supplementary-material"} and [S2](#mmc3){ref-type="supplementary-material"}, respectively.Figure 2Systematic Assignment of Latent Variables to Cell Clusters Allows Identification of Cell Types Based on Their Phenotype or Function(A) Schematic of the framework to derive pathway activities and assign them to cell subsets.(B--F) (B) Heatmap of the KEGG collection\'s gene sets assigned to cell clusters in RA. The reported value represents the coefficient of the regression model and the "\# loadings" color scale represents the number of latent variables that were found significant for that specific gene set. Factor weights for NK cell cytotoxicity gene set from the KEGG collection (C), B cell receptor signaling gene set from the KEGG collection (D), plasmacytoid dendritic cell signature from the C7 immunological signature collection (E), and type I interferon signaling gene set from the REACTOME collection (F).

OSMR Signaling Is Active in Specific Subsets of Rheumatoid Arthritis Fibroblasts that Share a Similar Inflammatory Profile to Stromal Cells from Patients with Inflammatory Bowel Disease {#sec2.3}
-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

By using latent variables as surrogates of pathway activities, we sought to discover novel pathways potentially involved in RA. We focused on Oncostatin M (OSM) receptor (OSMR) signaling, whose expression level was found to be low yet widespread across fibroblast subsets ([Figure 3](#fig3){ref-type="fig"}A). However, we found 17 latent factors enriched for OSMR signaling-related gene sets. We collapsed these redundant gene sets in four pathway activities ([Figure 3](#fig3){ref-type="fig"}B), which showed a distinct distribution and composition of fibroblast subsets ([Figures S4](#mmc1){ref-type="supplementary-material"}A and S4B). OSMR has been recently discovered to be a driver of increased inflammatory state of stromal cells in inflammatory bowel disease (IBD) ([@bib23]). To investigate whether the RA fibroblast populations with high OSMR pathway activity also exhibited a similar inflammatory phenotype, we retrieved the gene signature associated with OSMR-high expression ([@bib23]) and visualized the mean gene expression in the OSMR-signaling pathway activity ([Figure 3](#fig3){ref-type="fig"}C). Interestingly, two of the OSMR-related pathway activities showed a higher expression for the previously identified gene signature. Furthermore, these pathway activities seem to be mostly constituted by cells belonging to fibroblast clusters 1 and 2, which exhibit sublining markers ([Figures S4](#mmc1){ref-type="supplementary-material"}C and S4D). These results indicate that OSMR signaling is active in synovial sublining fibroblasts in RA; as these cells share an inflammatory gene signature with OSMR-high stromal cells from patients with IBD, they suggest that OSMR could be a potential driver of inflammation also in RA.Figure 3OSMR Signaling Is Active in Specific Subsets of Rheumatoid Arthritis Fibroblasts that Share a Similar Inflammatory Profile to Stromal Cells from Patients with Inflammatory Bowel Disease(A) Expression levels of OSMR across fibroblast clusters.(B) Correlation matrix of latent variables that maps to OSMR signaling pathways, as annotated by the METABASE gene set collection. Black frames enclose the correlation clusters that were selected to be representative of specific pathways activity.(C) Mean expression level of genes found to be associated with OSMR-high-stromal cells in IBD.

Integration of Ligand-Receptor Interactions Reveals MERTK-Driven Apoptotic Cell Clearance by a Monocyte Subset in Rheumatoid Arthritis {#sec2.4}
--------------------------------------------------------------------------------------------------------------------------------------

To further explore the potential of pathway activities to uncover novel gene signatures, we sought to integrate this information with ligand-receptor interaction analysis (see [Methods](#sec4){ref-type="sec"}). In short, the expression level of interacting ligands and receptors was correlated with, and filtered for, latent variables with a significant enrichment for pathways where either protein was present ([Figure 4](#fig4){ref-type="fig"}A). Among the filtered cellular interactions, we found GAS6-MERTK. MERTK has a distinct expression across monocyte subsets ([Figure 4](#fig4){ref-type="fig"}B), and both monocyte clusters 1 and 3 showed interactions with GAS6 in fibroblasts and B cells subsets via MERTK ([Figures S5](#mmc1){ref-type="supplementary-material"}A and S5B). We found MERTK-associated pathways to cluster in two main groups ([Figure 4](#fig4){ref-type="fig"}C): one with gene sets related to cell motility and cell signaling, the other one related to endocytosis and phagocytosis. As MERTK is a known marker for endocytic and phagocytic activity (particularly in the context of apoptotic cell clearance \[[@bib12]\]), we set up to assess whether cells that were showing an endocytic-related activity showed an efferocytosis signature ([@bib28]; [@bib39]). We observed that cells characterized by endocytic activity indeed recapitulated this gene signature to a higher degree as compared with the other activity clusters ([Figure 4](#fig4){ref-type="fig"}D). This cell subset, which is mostly constituted of monocytes from cluster 3 ([Figure S5](#mmc1){ref-type="supplementary-material"}C, see [Figure S5](#mmc1){ref-type="supplementary-material"}D for the signature enrichment across monocyte clusters), was found to be depleted in RA when compared with controls ([Figure 4](#fig4){ref-type="fig"}E), suggesting that reduced apoptotic cell clearance by MERTK-signaling monocytes could be a pathogenic mechanism in RA.Figure 4Integration of Ligand-Receptor Interactions Reveals MERTK-Driven Apoptotic Cell Clearance by a Monocyte Subset in Rheumatoid Arthritis(A) Ligand-receptor interaction network as computed by CellPhoneDB and filtered as described in the main text.(B) Expression levels of MERTK across monocyte clusters.(C) Correlation matrix of latent factors that are associated with MERTK expression. Black frames enclose the correlation clusters that were selected to be representative of specific pathways activities.(D) Mean expression levels of genes found to be associated with infiltrating macrophages showing an efferocytic activity.(E) Proportion of cell types from disease (RA) or control (OA) across monocytes clusters.

Discussion {#sec3}
==========

Latent factor models are a flexible approach to uncover transcriptional programs in an unsupervised fashion, thus allowing a functional annotation of cells in an unbiased way.

Here, we conducted an evaluation of four state-of-the-art latent factor models specifically developed for scRNA-seq data (scCoGAPS \[[@bib34]\], LDA \[[@bib2]; [@bib9]\], scHPF \[[@bib16]\], and scVI \[[@bib17]; [@bib35]\]), assessing stability, predictive power, and gene set coverage of latent variables across the dimensionality of the latent space. Although the four methods represent considerably different approaches to the latent factor modeling paradigm, our evaluation highlighted some of the strengths and weaknesses of these methods across different tasks and can be used as a starting point for selecting the method of choice depending on the user needs.

We devised a novel framework to collapse redundant gene sets into pathway activities and assign these to cell clusters. We show that such an approach is able to retrieve known cellular phenotypes and that it can be used to identify cell subpopulations based on existing cell identity signatures, without having to rely on marker genes. Although we focused on two autoimmune disease cohorts, the described framework is generally applicable to any scRNA-seq datasets and provides an intuitive way to directly define cell subpopulations based on their function or phenotype.

Importantly, we also show that our framework can be used to discover previously unidentified pathways active in specific cell subsets. Among the pathways activities we retrieved that were not previously reported by the authors of the original publication ([@bib44]), we noticed the OSM signaling pathway. Interestingly, OSM has been recently reported to be a key driver of intestinal inflammation in IBD and to be associated with response to anti-TNF therapy ([@bib23]). We showed that RA fibroblasts with an OSMR pathway activity also express higher levels of a gene signature associated with high expression of OSMR in IBD stromal cells. This points to the potential involvement of the OSM/OSMR axis in establishing the inflammatory microenvironment in patients with RA and suggests the pathway might be similarly dysregulated in RA and IBD. Of note, cells with increased OSMR signaling activity mainly belong to sublining fibroblast subsets. Since sublining fibroblasts have also been recently associated with a specific inflammatory phenotype ([@bib6]) (as opposed to a more cartilage degradation phenotype of the lining fibroblasts), we can speculate that the OSM pathway is one of the drivers of inflammation not only in IBD but also in RA.

Through integration of ligand-receptor interaction analysis with our approach, we recovered a link between GAS6 on B cells and fibroblasts and MERTK in monocytes. As one of the pathway activities correlated to MERTK expression related to endocytosis, and because MERTK is known to be involved in efferocytosis, we hypothesized that MERTK-expressing monocytes could be involved in apoptotic cell clearance. To test this, we evaluated the expression of genes part of an efferocytosis signature ([@bib28]; [@bib39]) and were able to show that this monocyte subset does indeed show expression of this signature and is depleted in disease. Interestingly, a recent report ([@bib1]) confirmed the presence of MERTK^+^ synovial macrophages driving remission in RA, thus substantiating our findings.

Limitations of the Study {#sec3.1}
------------------------

We acknowledge an important limitation of our study is the relatively small selection of the latent factor models we pick for our initial evaluation. Our selection was guided by previous evidence that they could extract relevant transcriptional signatures from scRNA-seq data, as well as by the availability of implementations at the time of the analysis. Inclusion of other matrix factorization models such as f-scLVM ([@bib4], [@bib3]) and consensus NMF ([@bib15]), or other deep learning approaches such as DCA ([@bib10]), would certainly make any benchmarking efforts more comprehensive.

Another limitation is that both scRNA-seq datasets we analyzed were generated with the CEL-Seq2 technology and had a relatively low number of cells compared with more recently generated datasets ([@bib20]; [@bib30]; [@bib31]). The inclusion of larger datasets generated with different technologies would benefit a more comprehensive benchmarking effort and could potentially lead to different conclusions regarding the performance of the latent factor methods across different tasks.

Finally, as our approach to map latent factors to pathway activities and assign these to cell subsets relies heavily on gene sets annotation, the quality of the resulting pathway activities is inevitably tied to the quality of the original gene sets in the collection. As such, some of the identified pathway activities might be false positives. One example is the olfactory transduction gene set from the KEGG collection, which was found to be significantly associated with 64 latent factors, further collapsed in 19 pathway activities. Therefore, we suggest that hypothesis-driven explorations of the pathways activities assignments are needed to draw meaningful interpretations.
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